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ABSTRACT
Introduction Chemotherapy or chemoradiotherapy is
the recommended treatment for small cell lung cancer
(SCLC), except in stage I disease where clinical
guidelines state there may be a role for surgery based on
favourable outcomes in case series. Evidence supporting
adjuvant chemotherapy in resected SCLC is limited but
this is widely offered.
Methods Data on 359 873 patients who were
diagnosed with a ﬁrst primary lung cancer in England
between 1998 and 2009 were grouped according to
histology (SCLC or non-SCLC (NSCLC)) and whether they
underwent a surgical resection. We explored their
survival using Kaplan–Meier analysis and Cox regression,
adjusting for age, sex, comorbidity and socioeconomic
status.
Results The survival of 465 patients with resected
SCLC was lower than patients with resected NSCLC
(5-year survival 31% and 45%, respectively), but much
higher than patients of either group who were not
resected (3%). The difference between resected SCLC
and NSCLC diminished with time after surgery. Survival
was superior for the subgroup of 198 ‘elective’ SCLC
cases where the diagnosis was most likely known before
resection than for the subgroup of 267 ‘incidental’ cases
where the SCLC diagnosis was likely to have been made
after resection.
Conclusions These data serve as a natural experiment
testing the survival after surgical management of SCLC
according to NSCLC principles. Patients with SCLC
treated surgically for early stage disease may have
survival outcomes that approach those of NSCLC,
supporting the emerging clinical practice of offering
surgical resection to selected patients with SCLC.
INTRODUCTION
The well-established division of primary malignant
tumours of the lung into small cell lung cancer
(SCLC) and non-SCLC (NSCLC) is due to the clear
difference in presentation and behaviour of the two
groups.1 SCLC proliferates more rapidly and has a
high propensity to metastasise. It is more respon-
sive to ﬁrst-line chemotherapy. Patients with SCLC
usually present with locally advanced or metastatic
disease because of the high mitotic index of this
disease and its propensity to early systemic metasta-
sis. In contrast, between 10% and 20% of patients
with NSCLC present with early stage disease (I or
II) and are potential candidates for surgical
resection.
Surgery is inappropriate for the majority of
patients with SCLC who present with locally
advanced or metastatic disease. These are treated
with chemotherapy (and often with thoracic and
prophylactic cranial radiotherapy), which is asso-
ciated with a high response rate but which is often
followed by subsequent relapse and eventual death.
Nevertheless, on rare occasions patients are identi-
ﬁed with SCLC histology and with early stage
disease potentially suitable for resection.2 In these
situations surgery may be offered, but with little
evidence available to guide the treating thoracic
surgeons and oncologists. Combination chemora-
diotherapy in highly selected ﬁt patients with
limited stage disease has been reported to result in
5-year survival of up to 26%.3
The MRC-UK randomised study published in
19734 showed that surgery made outcomes worse
for patients with SCLC and led to ﬁrm ideas
against surgery among clinicians for the next two
decades. In the intervening years, signiﬁcant
advances have been made in the staging of lung
cancer with CT and, more recently, positron emis-
sion tomography (PET) imaging. Recently there
have been a number of reports of patients being
treated with surgery for SCLC with apparently
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Key messages
What is the key question?
▸ What would be the survival outcome in
patients with SCLC if they were managed
surgically like patients with NSCLC?
What is the bottom line?
▸ Despite the inherent poor prognosis of SCLC,
surgically resected patients with SCLC have
5-year survival of 31% compared with 45% in
resected NSCLC and 3% in patients with
unresected lung cancer of either subtype.
Why read on?
▸ This is a nationally based clinical follow-up study
of 359 873 patients with lung cancer of whom a
large series of 465 were patients who were
resected with SCLC. The results support the
emerging clinical practice of offering surgical
resection to selected patients with SCLC.
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good results.5–7 The clinical relevance of these studies is limited
by the lack of an appropriate control group and small numbers
of patients treated over periods of many years.8 Furthermore,
many patients in these reports had a diagnosis of SCLC made
only at postoperative examination of the resection specimen so
that the working diagnosis at the time of decision to offer
surgery was NSCLC.9
We examined the lung cancer data in the National Cancer
Data Repository (NCDR), which includes information on surgi-
cal treatment. The primary outcome was survival of patients
with SCLC who underwent surgery in comparison with patients
with NSCLC, and speciﬁcally in the context of surgery taking
place after the diagnosis of SCLC (elective cases) or the diagno-
sis of SCLC being established subsequent to surgical resection
(incidental cases).
METHODS
Patient data
Information on 383 027 lung cancer diagnoses (ICD10 C33–
C34) in England between 1998 and 2009 was retrieved from
the NCDR. Cancers identiﬁed from a death certiﬁcate only
(20 778; 5%) were excluded. We included only records related
to the patients’ ﬁrst primary lung cancer, leading to the exclu-
sion of 1421 tumour records. We also excluded 955 patients
without a valid NHS number because they could not be linked
to the hospital episode statistics (HES) data. The analyses pre-
sented here thus include 359 873 patients with a ﬁrst primary
lung cancer (table 1).
Tumours were grouped according to the ICDO2 classiﬁcation.
SCLC was deﬁned by morphology codes 8041–8045. All
remaining codes, including cancers with unspeciﬁed histology
(34% of all cases; 5% of resected NSCLC cases) were classiﬁed
as NSCLC.
Information on surgical resection was retrieved from the
linked HES records. Types of surgical resections included were
as previously deﬁned10: lobectomy or bilobectomy (66%),
partial lobectomy or wedge resection (15%), pneumonectomy
(15%), sleeve resection (1%) and other less common procedures
(other or unspeciﬁed excisions of (lesions of) trachea, carina,
lung and chest wall, 4%). Data on surgery from 1 month before
to 6 months after the date of diagnosis were included. If patients
had more than one record of a relevant surgical procedure, the
ﬁrst procedure was used in the analysis. There was no informa-
tion available on tumour stage.
Socioeconomic deprivation was measured by lower super
output area of residence (each comprising a population of
around 1500 people) based on the income domain of the
Indices of Deprivation 2004, 2007, 2010, relevant to the year
of diagnosis and grouped into quintiles. Each patient was thus
assigned to a socioeconomic quintile based on their postcode of
residence at the time of the cancer diagnosis.
For each patient, comorbidity information was obtained using
diagnosis codes recorded in the HES. All diagnoses from 2 years
before to 3 months after the patient’s date of diagnosis were
classiﬁed according to the scores from the weighted Charlson
comorbidity index11 and modiﬁed to exclude cancer itself as a
comorbid condition. The resulting scores were aggregated into
categories of increasing severity of comorbidity.
The cancer registration record included a date of diagnosis,
preferably taken as the date of sampling of the tissue that gave
rise to the histological diagnosis. By considering the date of
diagnosis and the date of the surgical resection, we attempted to
further classify the resected SCLC into those (elective) cases
that were known (typically from an earlier diagnostic biopsy) to
be SCLC before the surgical resection was planned, and those
(incidental) cases that were diagnosed as SCLC on the basis of
the examination of the resection specimen. We considered
those with a resection on day 8 after the SCLC diagnosis or
later to be predominantly elective cases (n=198; table 2).
When the resection was earlier than the date of diagnosis or
near the date of diagnosis (range from 28 days before the diag-
nosis to 7 days after), we considered it most likely that the diag-
nosis was established as SCLC on the basis of the resected tissue
(n=267).
In a small minority of cases of resection taking place before
the diagnosis, this sequence of events occurs because the date of
diagnosis was taken to be the date of the pathology report
instead of the date of tissue sampling which may have occurred
earlier. These date sequences are not routinely quality assured
and we made no attempt to correct the very few outlying
values.
Data analysis
Survival functions curves were estimated for each group using
the Kaplan–Meier method and corresponding 5-year survival
estimates with 95% CI (corresponding to a p value criterion of
5%) were calculated.
Univariate and multivariate Cox proportional hazards ana-
lyses were performed to assess the all-cause mortality HRs
according to histological type and surgery, and adjusted for age,
sex, comorbidity and socioeconomic deprivation. These adjust-
ments were decided a priori.
Survival time was calculated from the date of surgery for
those patients undergoing surgical resection or date of diagnosis
for those who did not, until date of death from any cause. The
remaining patients were censored at the end of follow-up on 31
December 2010. The Cox regression analyses were divided into
three prespeciﬁed intervals of follow-up time: ﬁrst month of
follow-up, intermediate period from 1 month to 1 year, and
long-term follow-up (1 year and longer).
All analyses were performed using Stata V.11.0 (StataCorp LP,
College Station, Texas, USA).
Table 1 Lung cancer registrations in England 1998–2009
Histology Surgery
No Yes Yes (%) Total
NSCLC 284 355 29 670 9 314 025
SCLC 45 383 465 1 45 848
SCLC (%) 14 2 13
Total 329 738 30 135 8 359 873
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.
Table 2 Interval from diagnosis to operation in 465 patients with
SCLC with surgical resection
Days Frequency % Subgroup
−28 to −8 4 1 Incidental
−7 to −2 14 3 Incidental
−1 to 1 236 51 Incidental
2 to 7 13 3 Incidental
8 to 176 198 43 Elective
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RESULTS
Of the 359 873 lung cancer diagnoses during the 12-year
period from 1998 to 2009, 45 848 (13%) were SCLC of which
465 (1% of all SCLC) were treated surgically (table 1). By com-
parison, of the 314 025 patients with NSCLC, 29 670 (9%)
underwent surgical resection. The survival functions for the
four groups of patients are presented in ﬁgure 1. Five-year sur-
vival was superior for patients with NSCLC who underwent a
surgical resection at 45% (95% CI 44% to 46%). Five-year sur-
vival among patients with SCLC who underwent a surgical
resection was lower at 31% (95% CI 26% to 36%), but consid-
erably higher than the survival among unresected patients with
NSCLC (2.72% (95% CI 2.66% to 2.79%)) and those with
unresected SCLC (3.08% (95% CI 2.91% to 3.26%)).
Figure 2 shows the further subclassiﬁcation of resected SCLC
cases depending on the time between diagnosis and resection.
The subgroup dominated by an incidental SCLC diagnosis
(green survival function) had lower survival than the subgroup
dominated by an elective resection of known SCLC (red survival
function), but the two survival functions were similar and con-
verged from the third year of follow-up onwards.
Table 3 shows the results of multivariate Cox regression ana-
lysis comparing the survival of all ﬁve groups of lung cancer
patients. Compared with the baseline group of resected NSCLC,
the survival of unresected groups with either histology was
inferior throughout the period of follow-up.
In the ﬁrst month of follow-up, survival of cases of electively
resected SCLC were identical to cases of the resected NSCLC
(mortality HR=0.98; 95% CI 0.46 to 2.05) but, in the longer,
term these electively resected SCLC patients had higher death
rates than resected NSCLC patients (1 month to 1 year: 1.36
(95% CI 1.00 to 1.84); ≥1 year: 1.47 (95 CI 1.18 to 1.82)).
The subgroup of incidentally resected SCLC cases initially had
an HR of 2.24 compared with resected NSCLC cases but this
excess decreased subsequently (1 month to 1 year: 1.65 (95%
CI 1.29 to 2.11); ≥1 year: 1.38 (95% CI 1.13 to 1.68)).
In the direct comparison of the two resected SCLC groups
(elective and incidental), the difference was large and statistically
Figure 1 Kaplan–Meier survival
analysis of resected and unresected
patients with non-small cell lung
cancer (NSCLC) and small cell lung
cancer (SCLC). For the resected
patients, follow-up starts on the date
of resection; for unresected patients it
starts on the date of diagnosis.
Figure 2 Kaplan–Meier survival
analysis of resected and unresected
patients with non-small cell lung
cancer (NSCLC) and small cell lung
cancer (SCLC). Resected SCLC cases
stratiﬁed into elective and incidental
cases as deﬁned in table 2. For the
resected patients, follow-up starts on
the date of resection; for unresected
patients it starts on the date of
diagnosis.
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signiﬁcant in the ﬁrst month but the HRs were more similar and
not statistically signiﬁcantly different after 1 month of
follow-up. The estimated HRs were generally not sensitive to
the statistical adjustment for comorbidity and socioeconomic
deprivation.
Of the resected SCLC patients, 275 (59%) had a lobectomy
or bilobectomy and 146 (31%) had a pneumonectomy. The
hazard of death was overall higher in patients with pneumonec-
tomy (adjusted HR 1.53; 95% CI 1.05 to 2.25). Forty-four
(9%) of the patients had other operations and had an intermedi-
ate hazard of death (HR 1.39; 95% CI 1.08 to 1.78).
DISCUSSION
The results of our analysis of the English NCDR data on out-
comes for surgery in SCLC suggest long-term survival outcomes
approaching those in resected NSCLC, especially for the cohort
of patients with SCLC who underwent elective resection. We
deduce that surgery was elective in those cases in which histo-
logical diagnosis was determined in advance of surgery.
Comparison of these results with other studies is difﬁcult
because the literature in this area is based mostly on small single
institution series.7 One other population-based study based on
Surveillance, Epidemiology and End Results (SEER) program
registry data showed a comparable ﬁve-year survival for patients
undergoing surgery for SCLC of about 40%.5
Case selection may have contributed to the differences we
report in outcomes for elective versus incidental surgery for
SCLC. It is plausible that patients with known SCLC were more
intensively worked up, with surgery offered only to those with
very early stage, few comorbidities and good performance
status. This could distort a comparison against outcome in
patients who underwent surgery for NSCLC. Patients with
NSCLC might be expected to have been offered surgery despite
a relatively more advanced stage (including patients with stage
IIIA) and more signiﬁcant comorbidities than those with SCLC
because surgery is a more accepted treatment modality in
patients with NSCLC. For these reasons it is difﬁcult to make
clear comparative inferences on survival between resected SCLC
and NSCLC in the absence of precise information on stage.
Nevertheless, we report ﬁve-year overall survival of 31% in
patients undergoing resection for SCLC. Perhaps the most per-
tinent comparison would be against those patients with a similar
stage and comorbidity undergoing medical treatment.
A major limitation of the present study is the lack of informa-
tion on stage and the inability to undertake a stage-adjusted com-
parison. This is because stage was not collected systematically by
the cancer registries in this period, and the 6th edition of the
TNM classiﬁcation did not specify T, N and M dimensions for
SCLC but by classiﬁcation of limited or extensive disease.1 12
Data from the US SEER registry, however, did report better out-
comes in patients with SCLC who underwent surgery compared
with medical treatment, both in stage I and stage II.5
A further limitation is the absence of information on treat-
ments other than surgery. The NCDR data that we used for this
study do not yet include information on radiotherapy and
chemotherapy. It is planned to amend these data in coming ver-
sions, and it will be especially relevant then to compare the sur-
vival of resected SCLC patients with that of patients with SCLC
on other lines of active therapy such as combined
chemoradiotherapy.
It is possible that, among SCLCs, some tumours have a more
favourable growth pattern and less aggressive tumour biology.
Incidentally resected patients with SCLC usually present with a
small peripheral nodule without hilar or mediastinal lymphaden-
opathy. This clinical presentation is unusual as SCLC usually
presents with advanced or locally advanced disease. Although
variations in tumour biology have not been reported, they may
account for the marked variation in clinical presentation and
outcome among patients with SCLC.
Published guidelines are not fully consistent on recommenda-
tions concerning the surgical management of SCLC,13–15 reﬂect-
ing the paucity of evidence in this area.
The difference between survival in resected and non-resected
SCLC patients may seem impressive, but there is strong selection
of patients for surgery and this comparison is biased by stage
and other case mix variables so it is not a fair representation of
the efﬁcacy of surgical resection in SCLC. The more relevant
comparison is between resected SCLC patients in the incidental
subgroup and resected NSCLC patients. This contrast addresses
the relevant clinical question: “What would be the survival
outcome in SCLC patients if they were managed surgically like
NSCLC patients?” Comparison of the available case mix vari-
ables between these two groups (sex, age, socioeconomic status,
comorbidity and ethnicity) did not reveal any important differ-
ences, so the natural experiment is not confounded by those
factors.
Data have been continuously gathering in the last few years in
support of the role of surgery for SCLC but, in the absence of
clinical trial evidence, the uptake for surgery is likely to remain
low and patchy.
Previous major randomised trials of surgery for SCLC were
performed in the era prior to PET, with clinical staging and pre-
operative selection based on either plain chest ﬁlm4 or CT scan-
ning,16 which in part accounts for the high proportion of
exploratory thoracotomies by the inclusion of patients not cur-
rently accepted to be suitable for surgery. Many surgical series
Table 3 Survival among 359 873 lung cancer patients according to histological type and surgery
0–1 Month 1 Month–1 Year 1 Year +
Period of follow-up: HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
NSCLC with surgery (29 670) 1.00 1.00 1.00
SCLC with surgery (incidental) (267)* 2.24 1.45 3.45 <0.001 1.65 1.29 2.11 <0.001 1.38 1.13 1.68 0.002
SCLC with surgery (elective) (198)† 0.98 0.46 2.05 0.949 1.36 1.00 1.84 0.050 1.47 1.18 1.82 0.001
NSCLC, no surgery (284 355) 5.59 5.26 5.94 <0.001 6.76 6.57 6.96 <0.001 3.30 3.23 3.37 <0.001
SCLC, no surgery (45 383) 6.26 5.88 6.67 <0.001 6.59 6.39 6.80 <0.001 3.89 3.77 4.00 <0.001
Mortality HR adjusted for age, sex, comorbidity and socioeconomic deprivation.
*Diagnosis 7 days or less before resection. SCLC probably diagnosed from the resection specimen.
†Resection was 8 days or longer after diagnosis. SCLC diagnosis probably known before resection.
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.
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in selected patients report excellent survival; however, there is
no available evidence on the prognosis of a similar group of
patients treated with the current standard of concurrent chemor-
adiotherapy. The timing and need for a clinical trial has been
emphasised internationally.17 15 The purpose of such a study
would be to evaluate progression-free survival comparing
surgery with adjuvant chemotherapy versus concurrent chemor-
adiotherapy (ie, comparison of surgery against radiotherapy for
local control). There is likely to be strong opinions as to the
stage where clinical equipoise exists and, if so, pragmatic multi-
disciplinary team-based randomisation can perhaps be consid-
ered, as per the design of PulMiCC, a randomised clinical trial
comparing surgery versus no surgery for the treatment of colo-
rectal metastases to the lung.18
CONCLUSION
This nationally based cohort study of outcomes of surgery for
SCLC suggests good results may be obtained, despite the inher-
ent poor prognosis of SCLC. Carefully selected patients with
SCLC treated with surgery may have survival outcomes that
approach those of NSCLC. We suggest that any lung cancer
patient ﬁt for treatment should undergo full staging procedures
and that resection should be offered to patients with early stage
SCLC based on similar principles to those for NSCLC.
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